Healthcare -
Biotechnology - NASDAQ - US
$ 1.2
-15.3 %
$ 82 M
Market Cap
-2.03
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Zura Bio Limited
| Net Income | -52.4 M |
| Depreciation & Amortization | 9 K |
| Capital Expenditures | -75 K |
| Stock-Based Compensation | 16.8 M |
| Change in Working Capital | 2.31 M |
| Others | 7.52 M |
| Free Cash Flow | -28.2 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (52.4) | (60.6) | 3.5 | 8.4 |
| Depreciation & Amortization | 9 K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 16.8 | 9.7 | 0.3 | 0 |
| Other Operating Activities | 5.2 | 30.7 | (6.6) | (9.3) |
| Change in Working Capital | 2.3 | 5.1 | 1.6 | (0.2) |
| Cash From Operations | (28.1) | (15.1) | (1.1) | (1.1) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 75 K | (8.0) | (12.0) | 0 |
| Other Items | (5.0) | 0 | 0 | (139.4) |
| Cash From Investing Activities | (5.1) | (8.0) | (12.0) | (139.4) |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | (10.0) | 7.6 | (0.1) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 49.1 | 14.9 | 7.2 | 0.5 |
| Cash From Financing Activities | 109.8 | 121.3 | 0.4 | 141.2 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 76.7 | 98.2 | (0.7) | 0.7 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (28.2) | (23.1) | (13.1) | (1.1) |